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ABSTRACT
The prevalence of antimicrobial resistance for both Gram-positive and Gram-negative pathogens is
escalating worldwide. Outbreaks of community- and hospital-acquired methicillin-resistant Staphylo-
coccus aureus (MRSA) are being reported more frequently. Although antimicrobial resistance is well
recognised as a global problem, decisions about appropriate intervention and treatment should be made
at the level of the local hospital or healthcare system. Thus, local surveillance to identify prevalent
pathogens, detect bacterial resistance and identify particular strains is necessary for selecting optimal
treatment regimens. In addition, bactericidal antimicrobial agents with novel mechanisms of action and
activity against multidrug-resistant bacteria, together with improved infection control measures, are
needed to address this growing medical problem more effectively.
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THE EVOLUTION AND PREVALENCE
OF METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS
The prevalence of resistance to antimicrobial
agents has been increasing in many parts of the
world. Outbreaks of both community- and hospi-
tal-acquired methicillin-resistantStaphylococcus au-
reus (MRSA) are occurring more frequently [1];
Gram-negative pathogens such as Pseudomonas
aeruginosa, Acinetobacter spp. and Enterobacteria-
ceae are also becoming more resistant to first-line
antibiotics worldwide. Nonetheless, front-line
decisions about treatment must be made at the
local level, using local surveillance to identify
prevalent pathogens and associated resistance
patterns.
The evolution and prevalence of antimicrobial
resistance has been shown in a large study of
nosocomial bacteria from the intensive care units
of 300 hospitals in the USA; approximately 60%
of S. aureus and 90% of coagulase-negative
staphylococci such as Staphylococcus epidermidis
were resistant to b-lactams, setting them apart
from other resistant pathogens (Fig. 1) [2,3].
Patients with MRSA have an average hospital
stay 4.5 days longer than that of patients with
methicillin-susceptible S. aureus (MSSA). The
$16 575 per MRSA patient per hospital stay is
$4000 more than the cost of stay per methicillin-
susceptible S. aureus patient [4]. In 1997, it was
reported that MRSA accounted for 12% of all
nosocomial bacteraemias, 28% of all surgical
wound infections, and 21% of all nosocomial skin
infections [5–7]. Since a wide range of MRSA
prevalence has been found (Fig. 2), specific local
data, such as circulating bacterial strains, hospital
and unit rates, and identifiers of patients at risk, are
needed [8].
Not only has MRSA become one of the most
important pathogens responsible for nosocomial
infection, it has also become significant in commu-
nity-acquired infections; this has been most nota-
ble in the USA, but is also now becoming the case in
Europe and elsewhere. MRSA was first reported in
the UK in 1961 [9], only 1 year after the introduc-
tion of methicillin, an antibiotic developed to
combat bacterial resistance to penicillin. The first
documented MRSA outbreak in the USA occurred
in 1968 at a Boston hospital [10], but outbreaks
were undetected for many years because of inad-
equate detection procedures in most laboratories.
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MRSA has become a serious problem in the
UK, as well as in southern and western European
countries. The European Antimicrobial Resistance
Surveillance System (EARSS) shows that MRSA
prevalence varied from <1% in northern Europe
to >40% in southern and western Europe from
January 1999 to December 2002 (EARSS; available
at: http://www.rivm.nl.earss). In northern Eur-
ope, where stringent infection controls are in
place, resistant strains total less than 5% (Fig. 3).
Obviously, this reflects overall trends, rather than
site- or patient-specific data. Whether northern
Europe will be able to maintain its low MRSA
rates in the future remains to be seen.
MRSA has been implicated in a wide range of
diseases, from skin infections to systemic condi-
tions, including endocarditis, osteomyelitis, pneu-
monia, brain abscesses, meningitis, bacteraemia,
and toxinoses such as food poisoning, toxic shock
syndrome and other severe infections due to the
presence of various toxins, e.g., toxic shock
syndrome toxin or Panton–Valentine leukocidin,
especially in the community [11–13].
A comparison of the evolution of MRSA in three
European countries, the UK, France, and Denmark,
showed that antimicrobial resistance in the UK rose
sharply after it was first reported there in 1961. First
monoclonal and, thereafter, rapidly multiclonal
dissemination was responsible for this rise. There
was then a decrease during the 1980s, followed by
another sharp rise in the 1990s. Over the past few
years (from 2000 to 2005), resistance in the UK
appears to demonstrate a slow but steady increase
of approximately 2% per year, with several very
successful epidemic clones such as EMRSA-15 or
EMRSA-16 [1]. In France, resistance was reported
and began to rise a few weeks after the first report
appeared from the UK; the rise continued gradu-
ally through the late 1990s, and then began to drop
off around 2003 [14]. In Denmark, as in the UK and
France, there was first a sharp increase reported,
followed by a decrease in the early 1970s. Since
then, as has been the case in other northern
European countries, levels of MRSA resistance
have remained low [15,16]. This has been attrib-
uted to measures such as the isolation of carriers
and the tight control of antibiotic use [17,18].
MRSA has been reported to account for as
much as 89.5% of all S. aureus infections in some
hospitals in Russia [19]. Asian countries have also
experienced a growing prevalence of MRSA. In a
Taiwanese university hospital, levels rose from
26% in 1986 to 77% in 2001 [20]; in Korean
tertiary-care hospitals, levels were reported at
64% between 1999 and 2001 [21].
THERAPEUTIC OPTIONS FOR MRSA
INFECTIONS
In the face of increasing MRSA resistance, empir-
ical use of vancomycin has increased. However,
60
50
40
30
20
10
0
% Resistance
None 1%-3% 4%-10% 11%-25% 26%-50% >50%
%
 o
f l
ab
or
at
or
ie
s
Fig. 2. Importance of determining local resistance; oxacil-
lin resistance among Staphylococcus aureus from 494 hospi-
tal laboratories in the USA. Reproduced from Diekema
et al [8] with permission.
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Fig. 1. Challenge of increasing bacterial resistance.
Reproduced from NNIS [2] with permission. Pseudo,
Pseudomonas aeruginosa; K. pneumoniae, Klebiella
pneumoniae. CoNS, coagulase-negative Staphylococcus;
MRSA, methicillin-resistant Staphylococcus aureus; VRE,
vancomycin-resistant Enterococcus.
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vancomycin is less effective than b-lactams
against b-lactam-susceptible bacteria, acts slowly,
and requires monitoring [22] because of its bor-
derline activity and potential adverse effects.
Resistance to vancomycin and teicoplanin due to
VanA has emerged among Enterococcus strains,
leading to fears that few options might be avail-
able in the future for treating infections caused by
these pathogens [5,23,24]. In S. aureus, high-level
vancomycin-resistant MRSA strains, harbouring
the VanA determinant, have been reported only
in the USA [25]. Strains with decreased glycopep-
tide susceptibility (glycopeptide-intermediate-
resistant S. aureus and glycopeptide-resistant
S. aureus) have been isolated during the last
20 years worldwide but have only recently been
recognised as epidemic strains after the modifi-
cation of detection procedures as suggested by
Hiramatsu [26]. In 1995, Mainardi et al. reported
the first epidemic with such strains [27], which
are indistinguishable from strains reported more
recently [27,28]. Still, vancomycin remains the
cornerstone of MRSA therapy, even as the phar-
maceutical industry has been intensifying efforts
to meet the growing demand for new effective
medications.
A NOVEL ANTI -MRSA
CEPHALOSPORIN
Ceftobiprole (Ro 63-9141, BAL9141), a new anti-
biotic designed to treat serious infections caused
by Gram-positive pathogens, including MRSA, is
the first broad-spectrum anti-MRSA cephalospo-
rin to enter phase III therapeutic trials. Prelimin-
ary results from trials in patients with
complicated skin and skin structure infections
(cSSSIs), including those caused by MRSA, show
that ceftobiprole is safe and well-tolerated and is
not inferior to vancomycin (46th ICAAC, abstract
L-1212). Ceftobiprole showed bactericidal activity
in vitro against 11 ⁄ 12 MRSA strains at a concen-
tration of two times its MIC; it was also bacteri-
cidal against penicillin-resistant Streptococcus
pneumoniae in an animal (murine) model [29].
Ceftobiprole was more active than any other
penicillin or cephalosporin against penicillin-
resistant S. pneumoniae [30]. It also shows good
activity against common Gram-negative patho-
gens such as ceftazidime-susceptible P. aeruginosa
and many Enterobacteriaceae (Table 1) [31,32],
and displays an interesting sub-MIC post-antibi-
otic effect [33,34]. Because of its activity against
MRSA, the FDA granted ceftobiprole fast-track
designation in March 2003, for the treatment of
cSSSIs caused by MRSA. In June 2004, ceftobipro-
le was granted an additional fast-track designa-
tion for the treatment of nosocomial pneumonia,
including ventilator-associated pneumonia
caused by MRSA (Eye on bacterial infections.
2005; available at: http://centerwatch.com/pro-
fessional/cwpipeline/eyeon_bacterial.html).
Ceftobiprole has a high affinity for the MRSA
target protein penicillin-binding protein 2¢. The
drug has also shown a low potential to select
resistant mutants in vitro, maintaining a low MIC
when compared to other drugs used in antimi-
crobial studies [29]. Its broad-spectrum activity
may allow its use as monotherapy for serious
nosocomial infections where combination therapy
would otherwise be required [35].
CEFTOBIPROLE AND
COMPARATORS AGAINST MRSA
Ceftobiprole has greater potency, and kills
MRSA faster than vancomycin [32]; two other
broad-spectrum antimicrobial agents intended for
Table 1. Noteworthy activity of
ceftobiprole
Pathogen
Ceftobiprole
(MIC50) Comparator MIC50
MRSA 2.0 Oxacillin >32
PRSP 0.25 Ceftriaxone 1.0
Enterococcus faecalis 0.5 Ampicillin 2.0
Enterobacter cloacae ⁄
Citrobacter freundii
(derepressed)
4.0 Cefotaxime
Cefepime
>64
1.0
Pseudomonas aeruginosa
(ceftazidime-susceptible)
2.0 Ceftazidime 4.0
MRSA, methicillin-resistant Staphylococcus aureus; PRSP, penicillin-resistant
Streptococcus pneumoniae.
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serious MRSA infections on the market, linezolid
and tigecycline, are essentially bacteriostatic
rather than bactericidal [35–38]. Linezolid can be
given intravenously as well as orally, and appears
to be more effective than vancomycin in treating
nosocomial MRSA pneumonia and cSSSIs [39,40].
However, resistance to linezolid, which was
approved in 2000, has been developing (46th
ICAAC, abstract C2-1157 and abstract C2-1147)
[41]. This might be explained by the low inhibi-
tory quotient and inadequate serum levels in
some patients (46th ICAAC, abstract A-1945).
Other recently developed antimicrobial agents
include quinopristin–dalfopristin, daptomycin,
tigecycline and dalbavancin. Of these newer
agents, only tigecycline is effective against both
Gram-negative and Gram-positive organisms
[37], whereas the other drugs do not have anti-
Gram-negative activity.
Dalbavancin and daptomycin are both narrow-
spectrum intravenous antimicrobial agents
intended for treatment of cSSSIs. Dalbavancin
blocks peptidoglycan and thereby inhibits bacter-
ial cell-wall synthesis [5,42]. Because of a long
half-life, dalbavancin may be given once a week
when treating infections caused by MRSA [43].
Dalbavancin is not active against vancomycin-
resistant Enterococcus and has a decreased activity
against glycopeptide-intermediate-resistant S. au-
reus [43]. Daptomycin is bactericidal in all growth
phases, and important for the treatment of deep-
seated infections, such as MRSA endocarditis or
osteomyelitis. However, daptomycin is not
recommended for pneumonia because its penet-
ration of lung tissue is poor, as it binds to
surfactant in the epithelial lining fluid [44]. There
is cross-resistance between daptomycin and gly-
copeptides in glycopeptide–intermediate-resist-
ant S. aureus because of the increased thickness
of the bacterial cell wall [45,46]. Quinupristin–
dalfopristin is a combination intravenous product
approved for cSSSIs and vancomycin-resistant
Enterococcus faecium infections; it binds to bacter-
ial RNA and prevents protein synthesis [45].
Side-effects such as myalgia, arthralgia and
thrombophlebitis have been observed with qui-
nupristin–dalfopristin [47].
The choice of treatment for vancomycin-resist-
ant MRSA depends on the site of the infection,
antimicrobial activity, pharmacokinetics, safety
profile and resistance potential of the agent, and
the cost to the patient and institution [48].
As the introduction of new antimicrobial agents
is eagerly anticipated, rational and well-directed
use of new products, combined with ongoing
local surveillance systems, effective infection con-
trol measures, and identification of evolving and
deleterious strains, is required to prevent the
rapid emergence of antimicrobial resistance and
preserve the long-term utility of these agents.
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